Diamyd Medical’s phase 3 diabetes trial passes final safety review
Investing.com - Stifel has reiterated its Buy rating and $125.00 price target on Boston Scientific (NYSE:BSX), currently trading at $97.63, following the medical device maker’s biennial investor day event. According to InvestingPro data, the company commands a substantial market cap of $144.66 billion and has achieved impressive revenue growth of 21.44% over the last twelve months.
The research firm highlighted Boston Scientific’s "compelling innovation, deep pipeline, and strong management bench" as key factors supporting its recommendation. InvestingPro analysis confirms this outlook, with the company receiving a "GREAT" financial health score and showing strong momentum in the Healthcare Equipment & Supplies sector.
Boston Scientific unveiled its 2026-2028 long-range plan, projecting approximately 10%+ revenue growth throughout the period, along with 50 basis points of annual operating margin expansion.
Stifel noted that Boston Scientific has historically provided "prudent, achievable guidance" at analyst meetings that was ultimately exceeded, pointing to examples from 2021 and 2023 where the company outperformed its initial growth projections.
The firm expressed particular impressment with "the immense breadth and depth" of Boston Scientific’s innovation pipeline, which supports its positive outlook on the medical device company.
In other recent news, Boston Scientific has garnered significant attention from several analyst firms following its investor day presentations. The company reaffirmed its fiscal year 2025 organic sales growth forecast of 14-15% and outlined a long-term growth projection of at least 10% annually. Piper Sandler reiterated its Overweight rating, expressing confidence in Boston Scientific’s financial guidance for 2026 through 2028. Bernstein SocGen Group maintained an Outperform rating, highlighting the company’s strong long-range plan with an expected organic sales compound annual growth rate of over 10%. Oppenheimer also reiterated an Outperform rating, noting the company’s goals for adjusted operating margin expansion and double-digit EPS growth. Truist Securities raised its price target to $129, citing the company’s projections for over 10% organic revenue growth and margin expansion. Canaccord Genuity increased its price target to $132, emphasizing Boston Scientific’s strategy for growth and margin improvement. These developments indicate a positive outlook from multiple analysts on Boston Scientific’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.